Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Liabilities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 93.81% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, down 93.81% year-over-year, with the annual reading at $1.8 million for FY2025, 93.81% down from the prior year.
  • Other Non-Current Liabilities hit $1.8 million in Q4 2025 for Coherus Oncology, down from $17.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $29.3 million in Q4 2024 to a low of $53000.0 in Q1 2025.
  • Historically, Other Non-Current Liabilities has averaged $6.5 million across 5 years, with a median of $905000.0 in 2021.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 27053.92% in 2024 and later crashed 98.06% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $750000.0 in 2021, then skyrocketed by 362.27% to $3.5 million in 2022, then surged by 262.3% to $12.6 million in 2023, then surged by 133.49% to $29.3 million in 2024, then plummeted by 93.81% to $1.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for CHRS at $1.8 million in Q4 2025, $17.5 million in Q3 2025, and $1.5 million in Q2 2025.